A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A northern California oncology group study

C. Jacobs, Frederick J Meyers, C. Hendrickson, M. Kohler, S. Carter

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Eighty patients with recurrent squamous cell cancer of the head and neck were randomized to cisplatin (80 mg/m2) every 3 weeks or cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin. The overall response rate to cisplatin was 18%, with 10% complete responses. The overall response to the combination was 33% with 18% complete responses (P - 0.11). There was no difference in response duration, time to progression, or survival. There was no difference in renal toxicity between the 2 arms (creatinine > 2 mg/dl in 6% of the patients). There was significantly more leukopenia (64%), thrombocytopenia (18%), anemia (18%), and mucositis (33%) in the combination arm. This combination of two of the best agents for head and neck cancer did not improve response, but resulted in added toxicity.

Original languageEnglish (US)
Pages (from-to)1563-1569
Number of pages7
JournalCancer
Volume52
Issue number9
StatePublished - 1983
Externally publishedYes

Fingerprint

Methotrexate
Cisplatin
Head and Neck Neoplasms
Squamous Cell Neoplasms
Mucositis
Leucovorin
Leukopenia
Thrombocytopenia
Anemia
Creatinine
Kidney
Survival
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A northern California oncology group study. / Jacobs, C.; Meyers, Frederick J; Hendrickson, C.; Kohler, M.; Carter, S.

In: Cancer, Vol. 52, No. 9, 1983, p. 1563-1569.

Research output: Contribution to journalArticle

@article{d7e5b93980204ed8b5a17356864fb938,
title = "A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A northern California oncology group study",
abstract = "Eighty patients with recurrent squamous cell cancer of the head and neck were randomized to cisplatin (80 mg/m2) every 3 weeks or cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin. The overall response rate to cisplatin was 18{\%}, with 10{\%} complete responses. The overall response to the combination was 33{\%} with 18{\%} complete responses (P - 0.11). There was no difference in response duration, time to progression, or survival. There was no difference in renal toxicity between the 2 arms (creatinine > 2 mg/dl in 6{\%} of the patients). There was significantly more leukopenia (64{\%}), thrombocytopenia (18{\%}), anemia (18{\%}), and mucositis (33{\%}) in the combination arm. This combination of two of the best agents for head and neck cancer did not improve response, but resulted in added toxicity.",
author = "C. Jacobs and Meyers, {Frederick J} and C. Hendrickson and M. Kohler and S. Carter",
year = "1983",
language = "English (US)",
volume = "52",
pages = "1563--1569",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A northern California oncology group study

AU - Jacobs, C.

AU - Meyers, Frederick J

AU - Hendrickson, C.

AU - Kohler, M.

AU - Carter, S.

PY - 1983

Y1 - 1983

N2 - Eighty patients with recurrent squamous cell cancer of the head and neck were randomized to cisplatin (80 mg/m2) every 3 weeks or cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin. The overall response rate to cisplatin was 18%, with 10% complete responses. The overall response to the combination was 33% with 18% complete responses (P - 0.11). There was no difference in response duration, time to progression, or survival. There was no difference in renal toxicity between the 2 arms (creatinine > 2 mg/dl in 6% of the patients). There was significantly more leukopenia (64%), thrombocytopenia (18%), anemia (18%), and mucositis (33%) in the combination arm. This combination of two of the best agents for head and neck cancer did not improve response, but resulted in added toxicity.

AB - Eighty patients with recurrent squamous cell cancer of the head and neck were randomized to cisplatin (80 mg/m2) every 3 weeks or cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin. The overall response rate to cisplatin was 18%, with 10% complete responses. The overall response to the combination was 33% with 18% complete responses (P - 0.11). There was no difference in response duration, time to progression, or survival. There was no difference in renal toxicity between the 2 arms (creatinine > 2 mg/dl in 6% of the patients). There was significantly more leukopenia (64%), thrombocytopenia (18%), anemia (18%), and mucositis (33%) in the combination arm. This combination of two of the best agents for head and neck cancer did not improve response, but resulted in added toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0020601058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020601058&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 1563

EP - 1569

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -